Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Immunocore dosed the first patient in a Phase 1 trial of IMC-S118AI, its first autoimmune disease candidate, for type 1 diabetes. The dose-escalation study will evaluate safety, pharmacokinetics and clinical activity in patients with a specific genetic marker. The tissue-targeted therapy is designed to protect insulin
The first patient has been dosed in the Phase 1 trial of IMC-S118AI, Immunocore’s tissue-specific autoimmune candidate for type 1 diabetes.
Immunocore Hldgs (NASDAQ: IMCR ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Immunocore H